Histrelin

Histrelin is a synthetic nonapeptide analogue of gonadotropin-releasing hormone and one of the most potent GnRH agonists described. It carries a benzyl-protected D-histidine at position 6 and a C-terminal proline ethylamide, modifications that markedly increase receptor affinity and resistance to degradation. In the United States it is marketed in a long-duration hydrogel reservoir formulation as Supprelin LA for central precocious puberty, and previously as Vantas for advanced prostate cancer.

Histrelin is of interest to researchers studying continuous, near-constant GnRH receptor exposure, because its reservoir design releases peptide steadily over many months. This allows investigation of long-term pituitary suppression without the peaks and troughs associated with shorter formulations. Studies of central precocious puberty have used it to examine how suppression of the reproductive axis affects growth velocity, skeletal maturation and later recovery of pubertal development. It also contributes to the broader comparative literature on how GnRH agonist potency and release kinetics relate to the depth of sex-steroid suppression.

Histrelin binds GnRH receptors on anterior pituitary gonadotrophs with very high affinity. As with other superagonists, early exposure stimulates luteinising hormone and follicle-stimulating hormone release. Continuous release from its reservoir formulation then maintains uninterrupted receptor occupancy, producing desensitisation, receptor internalisation and suppressed gonadotropin synthesis. The outcome is sustained reduction of gonadal sex-steroid production for the life of the formulation. Because suppression depends on ongoing receptor exposure, it is reversible: reproductive axis activity resumes after the formulation is removed, a feature examined in recovery studies in central precocious puberty research.